You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

122 search results for: expert insights

expert video

Factors Associated With Development of Atopic Comorbidities in AD

1 min

Dermatology

Dr. Paller discusses factors influencing AD chronicity and comorbidities, focusing on disease severity, early onset, heredity, multiple allergies, and urban living as important in evaluating AD’s lasting effects on children.

expert video

Most Children With Atopic Dermatitis Have Uncontrolled Disease

1 min

Dermatology

Examine evidence from PEDI-BURDEN for the risk of flares in children with moderate-to-severe atopic dermatitis – a short soundbite from EADV 2022.

expert video

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

2 min

Dermatology

Dr. Weidinger discusses the intricate neuroinflammatory mechanisms of chronic pruritic skin disease such as AD and PN.

expert video

Most Burdensome Symptoms Rated by PN Patients

1 min

Dermatology

Dr. Chovatiya discusses the impact of pruritus on patients with PN.

expert video

The Risks of Associated Systemic and Atopic Comorbidities with AD

5 min

Dermatology

Dr. Paller explores the multifaceted impact of AD, highlighting its association with various comorbidities such as food allergies, asthma, allergic rhinitis, and mental health disorders.

expert video

When is the right time to consider a biologic in patients with CRSwNP?

5 min

Rhinology

Prof. Hellings and Prof. Corso explain that the right time to implement a biologic depends on academic and reimbursement criteria, which vary by country.

expert video

Association of Younger Age of Onset With Persistence of AD

1 min

Dermatology

Dr. Paller presents the Pediatric Eczema Elective Registry (PEER) findings, which suggest early-onset of AD is associated with higher risk of persistence of disease.

expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

5 min

Rhinology

Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.

expert video

The Role of Biomarkers in Clinical Decision-Making in Atopic Dermatitis

1 min

Dermatology

Dr. Stephan Weidinger talks about the role of biomarkers and their impact on clinical decision-making.

expert video

Current systemic therapies have been shown to induce remission in a subset of AD patients

5 min

Dermatology

Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.

expert video

Type 2 Inflammation in AD Manifestations in Skin and Body

6 min

Dermatology

Dr. Ramien discusses the role of type 2 inflammation in the pathophysiology of atopic dermatitis, and highlights the association of atopic dermatitis with systemic diseases and comorbidities.

expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

5 min

Rhinology

Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: MalaysiaChange country/region